# MBNL2

## Overview
MBNL2 (muscleblind-like 2) is a gene that encodes the muscleblind-like splicing regulator 2 protein, a crucial RNA-binding protein involved in the regulation of alternative splicing. This protein is characterized by its tandem zinc finger (TZF) domains, which facilitate its binding to specific RNA motifs, thereby influencing the splicing of pre-mRNA in muscle and neural tissues. MBNL2 plays a significant role in the development and function of the central nervous system, particularly in synaptic transmission and plasticity, and is essential for the transition from fetal to adult splicing patterns. Dysregulation of MBNL2 is implicated in various diseases, including myotonic dystrophy, where it is sequestered by expanded CUG repeat RNA, leading to splicing abnormalities. Additionally, MBNL2 has been associated with cancer progression, highlighting its importance in both normal cellular processes and disease states (Charizanis2012Muscleblindlike; Sznajder2016Mechanistic).

## Structure
The human muscleblind-like protein 2 (MBNL2) is characterized by its RNA binding domain, which includes four CCCH-type zinc finger motifs (ZF1-ZF4) that are crucial for its function in RNA splicing regulation. These zinc fingers are organized into two tandem zinc finger (TZF) domains: TZF12, comprising ZF1 and ZF2, and TZF34, comprising ZF3 and ZF4 (He2008Solution). 

The primary structure of MBNL2 includes sequences that form these zinc finger motifs, with ZF1 and ZF3 belonging to the CX7CX6CX3H type, and ZF2 and ZF4 to the CX7CX4CX3H type (He2008Solution). The secondary structure of these domains involves specific alpha-helices and beta-sheets, contributing to a compact global fold stabilized by hydrophobic interactions (He2008Solution). 

The tertiary structure of MBNL2's TZF domains is defined by the coordination of zinc ions through cysteine and histidine residues, forming a stable configuration that facilitates RNA binding (He2008Solution). The quaternary structure is not explicitly detailed in the context provided. MBNL2 may also undergo post-translational modifications such as phosphorylation and exists in several splice variant isoforms, which can influence its function and localization. The structural features of MBNL2 are essential for its role in recognizing and binding RNA, particularly in the context of myotonic dystrophy pathogenesis (He2008Solution).

## Function
MBNL2 (muscleblind-like splicing regulator 2) is a protein that plays a critical role in RNA splicing regulation, particularly in the context of muscle and neural tissue development. It is primarily active in the nucleus, where it binds to specific RNA sequences, influencing the alternative splicing of pre-mRNA. This regulation is crucial for the proper expression of various genes, impacting cellular differentiation and function (Charizanis2012Muscleblindlike).

In the developing brain, MBNL2 is involved in regulating synaptic transmission and plasticity. It is prominently expressed in the hippocampus and is essential for the developmental splicing program in the central nervous system (CNS). The loss of MBNL2 leads to misregulated splicing of hundreds of exons, which are similarly affected in conditions like myotonic dystrophy, indicating its importance in maintaining normal splicing patterns (Charizanis2012Muscleblindlike).

MBNL2 also plays a role in the regulation of cassette exons, promoting the transition from fetal to adult splicing patterns. This function is particularly significant in the postnatal development of the brain, where MBNL2 ensures the proper splicing of genes linked to neurological functions (Charizanis2012Muscleblindlike).

## Clinical Significance
MBNL2 (muscleblind-like splicing regulator 2) is implicated in several diseases, primarily due to its role in RNA splicing regulation. In myotonic dystrophy type 1 (DM1), a neuromuscular disorder, MBNL2 is sequestered by expanded (CUG)n repeats in DMPK transcripts, leading to disrupted RNA processing and aberrant alternative splicing. This results in the expression of fetal splice variants of various proteins, contributing to the disease pathology (André2019(CTG)n page 0 of 7). MBNL2 dysregulation in DM1 is associated with neurological symptoms, including abnormal REM sleep, spatial memory deficits, and impaired synaptic plasticity, as observed in Mbnl2 knockout mice (Charizanis2012Muscleblindlike).

In colorectal cancer, MBNL2 expression is decreased in tumor tissues compared to non-tumor samples, suggesting a role in promoting a less differentiated cancer cell phenotype. However, no significant association was found between MBNL2 expression and clinical factors such as tumor stage or patient survival (NAVVABI2021Altered). The altered expression of MBNL2 in various conditions highlights its clinical significance and potential as a therapeutic target.

## Interactions
MBNL2, a member of the muscleblind-like protein family, is involved in various interactions with RNA and other proteins, playing a crucial role in RNA splicing regulation. MBNL2 binds to RNA through its tandem zinc finger (TZF) domains, which are essential for its RNA-binding activity. These domains interact with specific RNA motifs, such as YGCY elements, particularly UGCU, to regulate alternative splicing (Charizanis2012Muscleblindlike; He2008Solution).

MBNL2 also interacts with expanded CUG and CCUG repeat RNA, which are associated with myotonic dystrophy types 1 and 2. This interaction leads to the sequestration of MBNL2 in nuclear foci, contributing to disease pathology (Sznajder2016Mechanistic). In addition to its RNA interactions, MBNL2 forms complexes with kinesin motor proteins, such as Kif1bα and Kif1c, through its zinc finger domains. This interaction is independent of RNA binding and is crucial for RNA localization and membrane anchoring in cells (Hildebrandt2022Muscleblindlike).

MBNL2's interactions extend to its role in cancer, where it regulates cancer cell migration and invasion through the PI3K/AKT-mediated epithelial-mesenchymal transition (EMT) pathway. It is targeted by miR-182, which inhibits MBNL2 expression, promoting cancer cell metastasis (Lin2021RNA-binding).


## References


1. (Hildebrandt2022Muscleblindlike) Muscleblind-like proteins use modular domains to localize RNAs by riding kinesins and docking to membranes. This article has 0 citations.

[2. (He2008Solution) Fahu He, Weirong Dang, Chikage Abe, Kengo Tsuda, Makoto Inoue, Satoru Watanabe, Naohiro Kobayashi, Takanori Kigawa, Takayoshi Matsuda, Takashi Yabuki, Masaaki Aoki, Eiko Seki, Takushi Harada, Yuri Tomabechi, Takaho Terada, Mikako Shirouzu, Akiko Tanaka, Peter Güntert, Yutaka Muto, and Shigeyuki Yokoyama. Solution structure of the rna binding domain in the human muscleblind‐like protein 2. Protein Science, 18(1):80–91, December 2008. URL: http://dx.doi.org/10.1002/pro.17, doi:10.1002/pro.17. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/pro.17)

[3. (Charizanis2012Muscleblindlike) Konstantinos Charizanis, Kuang-Yung Lee, Ranjan Batra, Marianne Goodwin, Chaolin Zhang, Yuan Yuan, Lily Shiue, Melissa Cline, Marina M. Scotti, Guangbin Xia, Ashok Kumar, Tetsuo Ashizawa, H. Brent Clark, Takashi Kimura, Masanori P. Takahashi, Harutoshi Fujimura, Kenji Jinnai, Hiroo Yoshikawa, Mário Gomes-Pereira, Geneviève Gourdon, Noriaki Sakai, Seiji Nishino, Thomas C. Foster, Manuel Ares, Robert B. Darnell, and Maurice S. Swanson. Muscleblind-like 2-mediated alternative splicing in the developing brain and dysregulation in myotonic dystrophy. Neuron, 75(3):437–450, August 2012. URL: http://dx.doi.org/10.1016/j.neuron.2012.05.029, doi:10.1016/j.neuron.2012.05.029. This article has 292 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.neuron.2012.05.029)

[4. (NAVVABI2021Altered) NAZILA NAVVABI, PAVLA KOLIKOVA, PETR HOSEK, FRANTISEK ZITRICKY, AZITA NAVVABI, ONDREJ VYCITAL, JAN BRUHA, RICHARD PALEK, JACHYM ROSENDORF, VACLAV LISKA, and PAVEL PITULE. Altered expression of mbnl family of alternative splicing factors in colorectal cancer. Cancer Genomics - Proteomics, 18(3):295–306, 2021. URL: http://dx.doi.org/10.21873/cgp.20260, doi:10.21873/cgp.20260. This article has 2 citations.](https://doi.org/10.21873/cgp.20260)

[5. (Sznajder2016Mechanistic) Łukasz J. Sznajder, Michał Michalak, Katarzyna Taylor, Piotr Cywoniuk, Michał Kabza, Agnieszka Wojtkowiak-Szlachcic, Magdalena Matłoka, Patryk Konieczny, and Krzysztof Sobczak. Mechanistic determinants of mbnl activity. Nucleic Acids Research, pages gkw915, October 2016. URL: http://dx.doi.org/10.1093/nar/gkw915, doi:10.1093/nar/gkw915. This article has 23 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1093/nar/gkw915)

[6. (Lin2021RNA-binding) Guanglan Lin, Jiao Li, Jin Cai, Haowei Zhang, Qilei Xin, Ningchao Wang, Weidong Xie, Yaou Zhang, and Naihan Xu. Rna-binding protein mbnl2 regulates cancer cell metastasis through mir-182-mbnl2-akt pathway. Journal of Cancer, 12(22):6715–6726, 2021. URL: http://dx.doi.org/10.7150/jca.62816, doi:10.7150/jca.62816. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.7150/jca.62816)